Ixazomib

3:18
Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?
Leon Bernal-Mizrachi
12:03
How will novel agents affect the amyloidosis population?
Morie Gertz et al.
4:28
Lenalidomide and Ixazomib: a successful amyloidosis treatment combination?
Oliver Charles Cohen
3:47
Palliative treatment of waldenström’s macroglobulinemia
Jorge Castillo
7:37
Prevention and management of adverse events in relapsed myeloma
Michel Delforge
1:01
Updates in amyloidosis: ISA 2020
Joan Bladé
3:02
Consolidation therapy options for myeloma post-transplant
Philip McCarthy
2:45
Myeloma: real-world data
Evangelos Terpos
3:59
Promising combination of ixazomib, lenalidomide & dex in high-risk smoldering myeloma
Mark Bustoros
04:22
Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
3:31
MAIA & TOURMALINE-MM3: updates in newly diagnosed multiple myeloma
Noopur Raje
1:58
Renal response to carfilzomib vs. bortezomib in R/R MM in the real world
Noopur Raje
1:44
Recent clinical trial updates for smoldering multiple myeloma
Irene Ghobrial
6:36
The definitive guide to multiple myeloma at ASH 2018: part V
Mohamad Mohty et al.
01:27
Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma
Vincent Rajkumar
1:08
Quadruplet regimens and antibodies for newly diagnosed multiple myeloma
Noopur Raje
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals